Immunome, Inc. (NASDAQ:IMNM – Get Free Report) shares hit a new 52-week low during mid-day trading on Friday. The company traded as low as $16.38 and last traded at $16.3930, with a volume of 561 shares traded. The stock had previously closed at $16.61.
Analyst Upgrades and Downgrades
Several research firms recently commented on IMNM. Truist Financial raised their target price on Immunome from $37.00 to $38.00 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. Wedbush reissued an “outperform” rating and set a $35.00 price objective on shares of Immunome in a report on Tuesday, October 27th. Piper Sandler reduced their target price on shares of Immunome from $33.00 to $30.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 10th. Wall Street Zen downgraded shares of Immunome from a “sell” rating to a “strong sell” rating in a research note on Sunday, October 4th. Finally, Alliance Global Partners began coverage on shares of Immunome in a report on Monday, September 21st. They issued a “buy” rating and a $32.00 target price on the stock. Fourteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $33.85.
Get Our Latest Stock Report on IMNM
Immunome Price Performance
The company has a market cap of $1.96 billion, a P/E ratio of -6.26 and a beta of 2.68. The business’s 50 day moving average price is $19.92 and its 200-day moving average price is $22.07.
Immunome (NASDAQ:IMNM – Get Free Report) last released its quarterly earnings results on Monday, November 9th. The company reported ($0.76) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.14). As a group, research analysts forecast that Immunome, Inc. will post -2.64 EPS for the current year.
Insider Buying and Selling
In other Immunome news, insider Jack Higgins sold 13,200 shares of the business’s stock in a transaction on Friday, September 11th. The stock was sold at an average price of $25.32, for a total value of $334,224.00. Following the transaction, the insider owned 65,050 shares of the company’s stock, valued at approximately $1,647,066. The trade was a 16.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 7.21% of the company’s stock.
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the business. Allworth Financial LP acquired a new position in Immunome during the 2nd quarter worth about $25,000. Integrated Wealth Concepts LLC bought a new stake in Immunome during the 2nd quarter worth about $27,000. KBC Group NV acquired a new stake in Immunome in the 1st quarter valued at about $60,000. GK Wealth Management LLC acquired a new stake in Immunome in the 3rd quarter valued at about $71,000. Finally, Sterling Capital Management LLC raised its stake in shares of Immunome by 840.0% in the third quarter. Sterling Capital Management LLC now owns 3,478 shares of the company’s stock worth $75,000 after acquiring an additional 3,108 shares during the last quarter. 44.58% of the stock is owned by institutional investors.
About Immunome
Immunome is a biotechnology company focused on discovering and developing therapies for cancer. It uses an antibody-discovery platform to identify targets and develop medicines intended to address areas of significant unmet medical need. The company’s research and development programs include targeted cancer treatments, such as antibody-based therapies and other drug candidates. Its portfolio has included investigational medicines for solid tumors and other cancers; these products are in development and are not necessarily approved for commercial use.
Further Reading
- Five stocks we like better than Immunome
- Palo Alto Networks’ Q1 Beat Gives Its Stock Rally Another Reason to Run
- Airfares Are Up, Flights Are Tight: 3 Airline Stocks Facing a Winter Test
- Hard Drives Were Left for Dead, But Seagate and Western Digital Are Soaring
- Tesla and SpaceX May Form a $3.4 Trillion Giant, But Who Really Benefits?
Receive News & Ratings for Immunome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunome and related companies with MarketBeat.com's FREE daily email newsletter.
